<p>波士顿，2026 年 5 月 7 日（全球新闻稿）——Cue Biopharma, Inc.（纳斯达克：CUE）今天宣布，2026 年 5 月 3 日，公司向七名新员工授予了诱导性股权奖励，包括新任总裁兼首席执行官林少李博士。该股权奖励是根据公司 2026 年诱导性股票激励计划授予的，并得到了公司独立董事的一致批准，作为每位新员工入职公司的诱导材料，符合纳斯达克上市规则 5635(c)(4)。</p>
<p>授予林博士的诱导性奖励包括（i）一项非法定股票期权，允许购买 655,074 股普通股，行使价格为每股 30.42 美元，该价格为 2026 年 5 月 1 日公司普通股在纳斯达克资本市场的收盘价，以及（ii）与 327,537 股普通股相关的限制性股票单位。林博士的期权将在她入职后的四年内按月均等分期归属，前提是她在每个适用的归属日期继续在公司工作。林博士的限制性股票单位奖励在授予时即完全归属。</p>
<p>授予其他六名新员工的诱导性奖励包括（i）非法定股票期权，允许购买总计 518,599 股普通股，行使价格为每股 30.42 美元，该价格为 2026 年 5 月 1 日公司普通股在纳斯达克资本市场的收盘价，以及（ii）与总计 327,534 股普通股相关的限制性股票单位奖励。期权奖励将在每位员工入职后的四年内按季度均等分期归属，前提是每位员工在每个适用的归属日期继续在公司工作。限制性股票单位奖励在授予时即完全归属。</p>
<p><strong>关于 Cue Biopharma</strong></p>
<p>Cue Biopharma（纳斯达克：CUE）是一家临床阶段的治疗公司，专注于推进一系列潜在的变革性疗法，旨在实现免疫系统疾病的功能性治愈。其主要资产是一种新型抗 IgE 抗体，具有双重作用机制，目前正在进行针对过敏性疾病的第二阶段开发。此外，Cue 开发了 Immuno-STAT®平台，能够选择性地在体内靶向特定疾病的 T 细胞，而不进行广泛的免疫调节。其主要自身免疫候选药物 CUE-401 正在向第一阶段推进，旨在调节炎症并促进 Treg 介导的耐受性。Cue 由一支经验丰富的管理团队领导，团队在识别、收购和推进有前景的药物候选者方面具有深厚的专业知识。</p>
<p><strong>投资者和媒体联系</strong></p>
<p>ir@cuebio.com</p>
<p>Cue Biopharma, Inc.</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE5qRTROQ00zTlRreE9ESXpJekl3T1RJMk9UST0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE5qRTROQ00zTlRreE9ESXpJekl3T1RJMk9UST0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjdmNzI1MDEtYzIyZC00ZTM5LWIzNGUtZjk0MWNkMWYxZTU4LTExMDQyNjMtMjAyNi0wNS0wNy1lbg==/tiny/Cue-Biopharma-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjdmNzI1MDEtYzIyZC00ZTM5LWIzNGUtZjk0MWNkMWYxZTU4LTExMDQyNjMtMjAyNi0wNS0wNy1lbg==/tiny/Cue-Biopharma-Inc-.png"/></p>

<p>Cue Biopharma, Inc.（纳斯达克代码：CUE）于 2026 年 5 月 3 日宣布向七名新员工授予诱导性股权奖励，包括首席执行官林少李。该奖励经独立董事批准，包括根据 2026 年诱导性股票激励计划授予的股票期权和限制性股票单位，符合纳斯达克上市规则 5635(c)(4)。林博士获得了 655,074 股的期权和 327,537 股的完全归属限制性股票单位。其他新员工获得了 518,599 股的期权和 327,534 股的完全归属单位。Cue Biopharma 专注于开发免疫系统疾病的治疗方案</p>

<p>BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), today announced that, on May 3, 2026, the Company granted inducement equity awards to seven new employees, including its newly appointed president and chief executive officer, Shao-Lee Lin, M.D., Ph.D. The equity awards were made pursuant to the Company’s 2026 Inducement Stock Incentive Plan and were unanimously approved by the independent directors of the Company as an inducement material to each new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>波士顿，2026 年 5 月 7 日（全球新闻稿）——Cue Biopharma, Inc.（纳斯达克：CUE）今天宣布，2026 年 5 月 3 日，公司向七名新员工授予了诱导性股权奖励，包括新任总裁兼首席执行官林少李博士。该股权奖励是根据公司 2026 年诱导性股票激励计划授予的，并得到了公司独立董事的一致批准，作为每位新员工入职公司的诱导材料，符合纳斯达克上市规则 5635(c)(4)。</p>
</div><p>The inducement grants made to Dr. Lin consisted of (i) a non-statutory stock option to purchase 655,074 shares of common stock, at an exercise price of $30.42 per share, which was the closing price of a share of the Company’s common stock on the Nasdaq Capital Market on May 1, 2026, and (ii) restricted stock units with respect to 327,537 shares of common stock. Dr. Lin’s option will vest in equal, monthly installments over four years from her start date, subject to continued employment with the Company through each applicable vesting date. Dr. Lin’s restricted stock unit award was fully vested upon grant.</p>
<div class="lb-trans"><p>授予林博士的诱导性奖励包括（i）一项非法定股票期权，允许购买 655,074 股普通股，行使价格为每股 30.42 美元，该价格为 2026 年 5 月 1 日公司普通股在纳斯达克资本市场的收盘价，以及（ii）与 327,537 股普通股相关的限制性股票单位。林博士的期权将在她入职后的四年内按月均等分期归属，前提是她在每个适用的归属日期继续在公司工作。林博士的限制性股票单位奖励在授予时即完全归属。</p>
</div><p>The inducement grants made to the six other new employees consisted of (i) non-statutory stock options to purchase an aggregate of 518,599 shares of common stock, at an exercise price of $30.42 per share, which was the closing price of a share of the Company’s common stock on the Nasdaq Capital Market on May 1, 2026, and (ii) restricted stock unit awards with respect to an aggregate of 327,534 shares of common stock. The option grants will vest in equal, quarterly installments over four years from each employee’s start date, subject to each employee’s continued employment with the Company through each applicable vesting date. The restricted stock unit awards were fully vested upon grant.</p>
<div class="lb-trans"><p>授予其他六名新员工的诱导性奖励包括（i）非法定股票期权，允许购买总计 518,599 股普通股，行使价格为每股 30.42 美元，该价格为 2026 年 5 月 1 日公司普通股在纳斯达克资本市场的收盘价，以及（ii）与总计 327,534 股普通股相关的限制性股票单位奖励。期权奖励将在每位员工入职后的四年内按季度均等分期归属，前提是每位员工在每个适用的归属日期继续在公司工作。限制性股票单位奖励在授予时即完全归属。</p>
</div><p><strong>About Cue Biopharma</strong></p>
<div class="lb-trans"><p><strong>关于 Cue Biopharma</strong></p>
</div><p>Cue Biopharma (Nasdaq: CUE) is a clinical stage therapeutics company focused on advancing a portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its lead asset is a novel anti-IgE antibody with a dual-mechanism of action, currently in Phase 2 development for allergic diseases. In addition, Cue developed the Immuno-STAT® platform which selectively targets disease-specific T cells in vivo without broad immune modulation. Its lead autoimmune candidate, CUE-401, is advancing towards Phase 1 and was designed to regulate inflammation and drive Treg-mediated tolerance. Cue is led by an experienced management team with deep expertise in identifying, acquiring, and advancing promising drug candidates.</p>
<div class="lb-trans"><p>Cue Biopharma（纳斯达克：CUE）是一家临床阶段的治疗公司，专注于推进一系列潜在的变革性疗法，旨在实现免疫系统疾病的功能性治愈。其主要资产是一种新型抗 IgE 抗体，具有双重作用机制，目前正在进行针对过敏性疾病的第二阶段开发。此外，Cue 开发了 Immuno-STAT®平台，能够选择性地在体内靶向特定疾病的 T 细胞，而不进行广泛的免疫调节。其主要自身免疫候选药物 CUE-401 正在向第一阶段推进，旨在调节炎症并促进 Treg 介导的耐受性。Cue 由一支经验丰富的管理团队领导，团队在识别、收购和推进有前景的药物候选者方面具有深厚的专业知识。</p>
</div><p><strong>Investor and Media Contact</strong></p>
<div class="lb-trans"><p><strong>投资者和媒体联系</strong></p>
</div><p>ir@cuebio.com</p>
<div class="lb-trans"><p>ir@cuebio.com</p>
</div><p>Cue Biopharma, Inc.</p>
<div class="lb-trans"><p>Cue Biopharma, Inc.</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE5qRTROQ00zTlRreE9ESXpJekl3T1RJMk9UST0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTcxNjE4NCM3NTkxODIzIzIwOTI2OTI="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjdmNzI1MDEtYzIyZC00ZTM5LWIzNGUtZjk0MWNkMWYxZTU4LTExMDQyNjMtMjAyNi0wNS0wNy1lbg==/tiny/Cue-Biopharma-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/YjdmNzI1MDEtYzIyZC00ZTM5LWIzNGUtZjk0MWNkMWYxZTU4LTExMDQyNjMtMjAyNi0wNS0wNy1lbg==/tiny/Cue-Biopharma-Inc-.png"/></p>

Cue BioPharma 根据纳斯达克上市规则 5635(c)(4) 报告了诱导性授予 | CUE 股票新闻